The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

Loss of ECRG4 expression decreases neutrophil mobilization from bone marrow reserves. by Katie D. Pool (20141584)

Subjects:

Youthful systemic milieu in young recipients decreased apoptosis and oxidative stress damage in allografts, and promoted proliferation. by Chengjun Yu (12136227)

CM-DWM-EC chart using 30% decrease in the mean for the E(KeV). by Shumaila Nisar (20114256)

“…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…”

Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. by Helal El-Zaatari (20442243)

“…<p>Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest.…”

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. by Guihua Wang (286390)

Bacterial abundance in L2 larvae collected from larval flasks inoculated with decreasing quantities of glycerol stock (bacteria source). by Margaret V. Becker (21387776)

Modelled policy outcomes, with posterior values for individual nodes ranked from 1-5 across the parties - Green, Reform UK, Liberal Democrat, Conservative, and Labour, where 1 is the lowest rank and 5 is the highest. The parties are ranked for each policy node in the network (e.g., income tax), based on the direction of change (“performance indicator”) stated in the first column (e.g., lowest, highest, most, improvement). For example, a value of 5 for Green tax means that green tax is lowest under Reform UK’s policies, while a value of 1 means that green tax is highest under the Green Party’s policies. Larger text in bold and italic font indicates that the directional change (i.e., increase or decrease) of a node under a party’s policies is consistent with the direction indicated, whereas black text indicates an opposite directional change (e.g., income tax is predicted to decrease under Reform UK in alignment with the performance indicator, and increase under Green and Labour). by Richard Stafford (174326)

“…Larger text in bold and italic font indicates that the directional change (i.e., increase or decrease) of a node under a party’s policies is consistent with the direction indicated, whereas black text indicates an opposite directional change (e.g., income tax is predicted to decrease under Reform UK in alignment with the performance indicator, and increase under Green and Labour).…”

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects: